Please assess the completion status of the following clinical trial:

Trial Title: EndoBarrier in Obese Subjects With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is willing and able to give informed consent for participation in the study.~* Type 2 diabetes~* BMI 30-49 kg/m²~* HbA1c ≥ 6.5% (48 mmol/mol)~* Appropriate life style intervention measures have been tried but have failed to achieve or maintain adequate, clinically beneficial weight loss for at least 6 months~* Person is generally fit for intervention~* Person commits to the need for long-term follow-up~Exclusion Criteria:~* Type 1 diabetes mellitus~* Maturity Onset Diabetes of the Young (MODY)~* Secondary diabetes due to a specific disease or glucocorticoid therapy~* Pregnancy or women of childbearing age without adequate contraception~* Women who are breast-feeding~* Hypothalamic cause of obesity, Cushing syndrome~* Major psychiatric disease including diagnosed eating disorders, history of drug or alcohol abuse~* History of bariatric surgery or complex abdominal surgery~* Inflammatory bowel disease~* Pancreatitis~* Cholelithiasis~* Uncontrolled gastroesophageal reflux~* Known upper GI bleeding conditions, e.g. gastric or esophageal varices~* Congenital or acquired abnormalities of the upper GI tract, e.g. stenosis~* Subjects with or a history of coagulopathy, upper gastro-intestinal bleeding conditions such as esophageal or gastric varices, congenital or acquired intestinal telangiectasia~* Chronic non-steroidal anti-inflammatory drug (NSAID) or aspirin treatment (Subjects unable to discontinue NSAIDs (non-steroidal anti-inflammatory drugs) during the implant period)~* Previous GI surgery that could affect the ability to place the device or the function of the implant~* GLP-1 receptor agonist therapy~* Known ischaemic heart disease or heart failure~* History of stroke~* Active Helicobacter pylori (Note: Subjects may be enrolled if they had a prior history of Helicobacter Pylori and were successfully treated)~* Iron deficiency and/or iron deficiency anemia~* Subjects or Family history of a known diagnosis or pre-existing symptoms of systemic lupus erythematosus, scleroderma or other autoimmune connective tissue disorder~* Known malignancy or any other multimorbid patient condition or circumstance, which, in the opinion of the investigator, would affect the patient's ability to participate in the protocol or would put the participant at an unjustified risk

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- EndoBarrier (Type: EXPERIMENTAL): EndoBarrier will be implemented for 9 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).